No Data
No Data
No Data
No Data
No Data
Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update
WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today
GlobeNewswireApr 30 19:00
Aclaris Therapeutics to Announce First Quarter 2024 Financial Results On May 7, 2024 and to Provide Corporate Update
PDF Version Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update April 30, 2024 WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) --
Aclaris TherapeuticsApr 30 12:00
Press Release: Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer PR Newswire CAMBRIDGE, Mass., April 23, 2024 CAMBRIDGE, Mass., April 23, 2024 /PRNewswire/ -- Flare Therapeutic
Dow JonesApr 23 20:01
Favourable Signals For Aclaris Therapeutics: Numerous Insiders Acquired Stock
Yahoo FinanceApr 11 22:12
Global Dermatological Therapeutics Market Analysis & Forecast 2024-2034 by Drug Class, Application and Region - Featuring Eli Lilly & Company, Amgen, Johnson & Johnson, and Aclaris Therapeutics Among Others
Yahoo FinanceApr 8 22:42
Board Changes Ahead of Aclaris Therapeutics Annual Meeting
Aclaris Therapeutics (ACRS) has provided an update.
TipRanksMar 20 04:43
No Data
No Data